Drug news
FDA approves Ryanodex for Malignant Hyperthermia - Eagle Pharma
The FDA has approved Ryanodex (dantrolene sodium), from Eagle Pharma, for injectable suspension indicated for the treatment of Malignant Hyperthermia (MH), along with the appropriate supportive measures. The FDA had designated Ryanodex as an Orphan Drug in August 2013. Eagle has been informed by the FDA that it will learn over the next four to six weeks if it has been granted the seven year Orphan Drug market exclusivity.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins